Abstract:Background and purpose: The pathophysiological features of acute ischemic stroke (AIS) often involve dysfunction of the blood-brain barrier (BBB), characterized by the degradation of tight junction proteins (Tjs) leading to increased permeability. This dysfunction can exacerbate cerebral injury and contribute to severe complications. The permeability of the BBB fluctuates during different stages of AIS and is influenced by various factors. Developing effective therapies to restore BBB function remains a significant challenge in AIS treatment. High levels of vascular endothelial growth factor (VEGF) in the early stages of AIS have been shown to worsen BBB breakdown and stroke progression. Our study aimed to investigate the protective effects of the VEGF receptor inhibitor Axitinib on BBB dysfunction and cerebral ischemia/reperfusion-induced injury. Methods: BEnd3 cell exposed to oxygen-glucose deprivation (OGD) model was constructed to estimate pharmacological activity of Axitinib (400 ng/ml) on anti-apoptosis and pathological barrier function recovery. In vivo, rats were subjected to a 1 h transient middle cerebral artery occlusion and 23 h reperfusion (tMCAO/R) to investigate the permeability of BBB and cerebral tissue damage. Axitinib was administered through the tail vein at the beginning of reperfusion. BBB integrity was assessed by Evans blue leakage and the expression levels of Tjs claudin-5 and occludin. Results: Our research revealed that co-incubation with Axitinib enhanced the cell viability of OGD-insulted bEnd3 cells, decreased LDH leakage rate, and suppressed the expression of apoptosis-related proteins cytochrome C and Bax. Axitinib also mitigated the damage to Tjs and facilitated the restoration of transepithelial electrical resistance in OGD-insulted bEnd.3 cells. In vivo, Axitinib administration reduced intracerebral Evans blue leakage and up-regulated the expression of Tjs in the penumbra brain tissue in tMCAO/R rats. Notably, 10 mg/kg Axitinib exerted a significant anti-ischemic effect by decreasing cerebral infarct volume and brain edema volume, improving neurological function, and reducing pro-inflammatory cytokines IL-6 and TNF-alpha in the brain. Conclusions: Our study highlights Axitinib as a potent protectant of blood-brain barrier function, capable of promoting pathological blood-brain barrier recovery through VEGF inhibition and increased expression of tight junction proteins in AIS. This suggests that VEGF antagonism within the first 24 h post-stroke could be a novel therapeutic approach to enhance blood-brain barrier function and mitigate ischemia-reperfusion injury.

Abstract TP17: SPAK Kinase Inhibitor ZT-1a Prevents Reactive Astrogliosis, Blood-Brain Barrier Breakdown, and Demyelination in a Mouse Model of VCID

SPAK inhibitor ZT‐1a attenuates reactive astrogliosis and oligodendrocyte degeneration in a mouse model of vascular dementia

Abstract P761: Reducing Reactive Astrocytes Improves Cognitive Function in a Mouse Model of Vascular Cognitive Impairment and Dementia

Efficacy of Novel SPAK Inhibitor ZT-1a Derivatives (1c, 1d, 1g & 1h) on Improving Post-Stroke Neurological Outcome and Brain Lesion in Mice

Modulation of brain cation-Cl- cotransport via the SPAK kinase inhibitor ZT-1a

The Protective Effects of Axitinib on Blood-Brain Barrier Dysfunction and Ischemia-Reperfusion Injury in Acute Ischemic Stroke

Abstract WP295: Blocking the VCAM1-VLA4 Axis Prevents Cognitive Decline in a Mouse Model of Infarct-Induced Neurodegeneration

Theta-burst transcranial magnetic stimulation attenuates chronic ischemic demyelination and vascular cognitive impairment in mice

Role of SPAK–NKCC1 signaling cascade in the choroid plexus blood–CSF barrier damage after stroke

Attenuating vascular stenosis-induced astrogliosis preserves white matter integrity and cognitive function

Apoptosis signal-regulating kinase 1 is a novel target molecule for cognitive impairment induced by chronic cerebral hypoperfusion

P4–054: Direct Angiotensin II Type 2 Receptor Stimulation by Compound 21 Prevents Vascular Dementia: Involvement of NMDA Receptor Activation

Dl-3-n-Butylphthalide Promotes Remyelination and Suppresses Inflammation by Regulating AMPK/SIRT1 and STAT3/NF-κB Signaling in Chronic Cerebral Hypoperfusion

Astroglial NF-kB contributes to white matter damage and cognitive impairment in a mouse model of vascular dementia

Hope for vascular cognitive impairment: Ac-YVAD-cmk as a novel treatment against white matter rarefaction

Abstract WMP114: EZH2 Inhibitor Improves Cognitive Behavior in CAA

Genetic knockout of myosin light chain kinase (MLCK210) prevents cerebral microhemorrhages and attenuates neuroinflammation in a mouse model of vascular cognitive impairment and dementia

Edaravone dexborneol ameliorates cognitive impairment by regulating the NF-κB pathway through AHR and promoting microglial polarization towards the M2 phenotype in mice with bilateral carotid artery stenosis (BCAS)

Abstract 85: Genetic Deficiency Of MiRNA-15a/16-1 Confers Resistance To Neuropathological Damages And Cognitive Dysfunction In Experimental Vascular Cognitive Impairment And Dementia

Deletion of the WNK3-SPAK Kinase Complex in Mice Improves Radiographic and Clinical Outcomes in Malignant Cerebral Edema after Ischemic Stroke.

Abstract WP496: Optogenetic Neuronal Stimulation Promotes Myelination after Subcortical Ischemic Vascular Dementia